Puma Biotechnology | PBYI - Cost Of Sales


Puma Biotechnology reported $29.1M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Exelixis USD 26.48M 7.91M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
Incyte USD 121.18M 22.18M Dec/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Moderna USD 207M 88M Sep/2025
Novartis USD 3.54B 217M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Takeda JPY 401.15B 184.07B Dec/2025
TG Therapeutics USD 28.09M 9.15M Sep/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025